Your browser doesn't support javascript.
loading
Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management.
Rabbani, Syed Arman; El-Tanani, Mohamed; Matalka, Ismail I; Rangraze, Imran Rashid; Aljabali, Alaa A A; Khan, Mohammad Ahmed; Tambuwala, Murtaza M.
Afiliación
  • Rabbani SA; RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates.
  • El-Tanani M; RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates.
  • Matalka II; RAK Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates.
  • Rangraze IR; Department of Pathology and Microbiology, Medicine, Jordan University of Science and Technology, Irbid, Jordan.
  • Aljabali AAA; Internal Medicine Department, RAK College of Medical Sciences, RAK Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates.
  • Khan MA; Department of Pharmaceutics and Pharmaceutical Technology, Yarmouk University, Irbid, Jordan.
  • Tambuwala MM; Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
Expert Rev Endocrinol Metab ; : 1-19, 2024 Aug 28.
Article en En | MEDLINE | ID: mdl-39194153
ABSTRACT

INTRODUCTION:

Incretin-based therapies have emerged as effective treatments for type 2 diabetes (T2D) and obesity. However, not all patients achieve optimal outcomes with existing treatments, highlighting the need for more effective solutions. AREAS COVERED We present a comprehensive evaluation of Tirzepatide (TZP), a novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonist, for managing obesity and T2D. We conducted a systematic search of Cochrane, PubMed, Scopus, and Web of Science databases from inception to April 2024. The focus of the review is on the development and therapeutic potential of TZP, with detailed exploration on pharmacodynamics, pharmacokinetics, clinical efficacy, and safety. Furthermore, it reviews TZP's impacts on glycemic control, weight management, and its potential cardiovascular (CV) benefits. EXPERT OPINION TZP represents a significant advancement in the dual-targeted approach to treating T2D and obesity. Its unique mechanism of action offers superior efficacy in reducing glycemic levels and body weight compared to existing therapies. New data suggesting improvements in CV outcomes indicate that TZP could set a new standard in the treatment paradigm. While long-term data on efficacy and safety are still forthcoming, current evidence positions TZP as a promising option for patients who have not reached their therapeutic goals with existing treatments.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Expert Rev Endocrinol Metab Año: 2024 Tipo del documento: Article País de afiliación: Emiratos Árabes Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Expert Rev Endocrinol Metab Año: 2024 Tipo del documento: Article País de afiliación: Emiratos Árabes Unidos Pais de publicación: Reino Unido